Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch + Lomb Corporation Common Shares (NY: BLCO )

16.41 -0.23 (-1.38%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 Next >
Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million
Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft. 
Via Benzinga
Bausch + Lomb Provides Update on Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
From Bausch + Lomb Corporation
Via Business Wire
Why Bausch + Lomb Rallied Today
The highly indebted healthcare stock rose on rumors it may be selling itself. 
Via The Motley Fool
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Government
Exposures Political
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Responds to Rumors of a Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
From Bausch + Lomb Corporation
Via Business Wire
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Third-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt
IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders. 
Via Benzinga
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day. 
Via Benzinga
Topics Bankruptcy Stocks
Exposures Financial Legal US Equities
This Advance Auto Parts Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Why Bausch + Lomb Stock Soared by Over 7% on Monday
It was quite a busy and eventful day for the company. 
Via The Motley Fool
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Government
Exposures Political
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
Via Benzinga
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
From Bausch + Lomb Corporation
Via Business Wire
Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.